Shares of Karyopharm Therapeutics Inc. (KPTI) took a dive on Tuesday. The reason? A classic biotech story: a pivotal clinical trial that delivered good news and bad news, leaving investors to sort out what it all means.

The trial in question is called SENTRY, a Phase 3 study testing a combination therapy for myelofibrosis. That's a rare, chronic blood cancer where bone marrow gets replaced by scar tissue, messing up normal blood cell production. Karyopharm was testing its drug, selinexor, in combination with an existing treatment called ruxolitinib.

Here's the split decision. The trial clearly hit its first major goal. It showed that adding selinexor to ruxolitinib led to a statistically significant improvement in reducing spleen volume. For patients, an enlarged spleen is a common and painful problem in myelofibrosis, so shrinking it is a big deal. Specifically, 50% of patients on the combo achieved a 35% or greater reduction in spleen volume at 24 weeks, compared to just 28% on ruxolitinib alone. The effect was rapid and sustained.

Even more intriguing was a signal on survival. The data suggested patients on the combination therapy saw a greater than 50% reduction in the risk of death compared to those on ruxolitinib alone. In oncology, a survival benefit is often the holy grail, so that's a point very much in the "good news" column.

Now for the "but." The trial did not meet its second main goal, which was improving patients' total symptom score. Symptoms for this disease can include severe fatigue, night sweats, and bone pain. Patients on the combo reported a 9.89-point improvement, which was actually slightly less than the 10.86-point improvement seen in patients on ruxolitinib alone. It missed the mark.

And the mixed bag continues. On other secondary measures—like how long patients lived without their disease getting worse, stabilizing hemoglobin levels, or improving bone marrow fibrosis—the trial didn't show a meaningful difference between the two groups. The company says it will keep evaluating these endpoints as the data matures.

So, what's next for this data? Karyopharm plans to present the full details at a future medical conference and submit the results to a peer-reviewed journal. The company believes the therapy could be included in relevant medical compendia—a key step for adoption—in the second half of 2026.

Perhaps anticipating the market's reaction to nuanced data, Karyopharm also announced a financial cushion. It closed a private placement raising about $30 million. The deal involved selling shares and pre-funded warrants. If all the accompanying warrants are exercised, the company could rake in an additional $44 million. It's a nice bit of near-term capital to have on hand.

Despite the stock's drop, Wall Street analysts watching the company haven't hit the panic button. The stock still carries a consensus Buy rating with an average price target of $42.17, which is a world away from its current trading level. Recent analyst actions include initiations with Buy and Overweight ratings from firms like Rodman & Renshaw and Cantor Fitzgerald.

When the dust settled on Tuesday, Karyopharm shares were down 17.43% at $6.04. It's a sharp reminder that in biotech investing, hitting one target and missing another can leave everyone parsing the data, wondering if the glass is half full or half empty.